Eran Kalmanovich, Pascal Battistella, Philippe Rouviere, Bernard Albat, Jean-Marc Frapier, Roland Demaria, Fabien Huet, Audrey Agullo, Marc Mourad, Pascal Colson, Florence Leclercq, Philippe Gaudard, François Roubille
Background: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surgery. Objectives: We report a single center experience of ten patients on dabigatran therapy who were given idarucizumab prior to heart transplantation. Methods & results: The mean plasma concentration of dabigatran prior to reversal was 139 ± 89 ng/ml...
February 15, 2021: Future Science OA